12 Results for "

CLK1-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "CLK1-IN-2" in MCE Product Catalog:

Cat. No.: HY-152219
CAS No.: 3029431-68-0
Purity:  98.15%
Target:  

CDK

Research Areas:  

Infection Cancer

CLK1-IN-2 is metabolically stable Clk1 inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC50 value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-112296
CAS No.: 2407433-00-3
Purity:  99.64%
Target:  

CDK Apoptosis DYRK

Research Areas:  

Cancer

T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-115470
CAS No.: 2109805-56-1
Purity:  98.63%
Target:  

CDK DYRK

Research Areas:  

Cancer

CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC50s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-123600
CAS No.: 2086809-58-5
Purity:  99.73%
Target:  

CDK

Research Areas:  

Others

SRI-29329 is a specific CLK inhibitor, with IC50 values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively .
loading...
    loading...
Cat. No.: HY-15951
CAS No.: 1285702-20-6
Synonyms: CID44968231; NCGC00188654
Target:  

CDK DYRK

Research Areas:  

Cancer

ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B .
loading...
    loading...
Cat. No.: HY-111379
CAS No.: 1425945-63-6
Purity:  97.38%
Target:  

DYRK CDK GSK-3

EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC50s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively .
loading...
    loading...
Cat. No.: HY-131978
CAS No.: 2587177-94-2
Purity:  98.27%
Target:  

CDK

Research Areas:  

Cancer

DB18 is a potent and selective inhibitor of CDC2-like kinases (CLKs), with IC50 values in the range of 10-30 nM for CLK1, CLK2 and CLK4. DB18 has anti-tumor activity .
loading...
    loading...
Cat. No.: HY-153708
CAS No.: 748142-15-6
Purity:  99.12%
Synonyms: CAF-170
Target:  

CDK

Research Areas:  

Cancer

SGC-CLK-1, a chemical probe, is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. SGC-CLK-1 can inhibit the growth of melanoma and glioblastoma cells .
loading...
    loading...
Cat. No.: HY-125290
CAS No.: 2275601-87-9
Purity:  99.50%
Target:  

CDK DYRK

Research Areas:  

Cancer

MU1210 (compound 12f), a chemical probe, is an inhibitor of CDC-like kinases Clk1, Clk2, and Clk4 (with IC50 values of 8, 20, and 12 nM respectively), with IC50 for HIPK1 and DYRK2 are 187 and 1309 nM. MU1210 also has favorable pharmacokinetic characteristics (in mice, 10 mg/kg, intraperitoneal injection: Cmax=1.24 μM, T1/2=58 minutes; no acute toxicity observed) .
loading...
    loading...
Cat. No.: HY-113831
CAS No.: 1005784-60-0
Target:  

CDK SRPK

Research Areas:  

Cancer

LK1/2-IN-3 (compound 3) is a potent and selective CLK1 and CLK2 inhibitor with IC50 values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs .
loading...
    loading...
Cat. No.: HY-125202
CAS No.: 2341841-06-1
Target:  

CDK DYRK

Research Areas:  

Cancer

KuWal151 is a CLK1, CLK2 and CLK4 inhibitor with a high selectivity margin towards DYRK kinases. KuWal151 has potent antiproliferative activity in an array of cultured cancer cell lines .
loading...
    loading...
Cat. No.: HY-183831
CAS No.: 3034312-19-8
Research Areas:  

Cancer

GPS167 is a CLK kinase inhibitor that potently and selectively inhibits recombinant human CLK1, CLK2 and CLK4. By inhibiting CLK-mediated phosphorylation of SRSF10, GPS167 upregulates the protein-binding ability of CLK1 and CLK4 with SRSF10, downregulates oncogenic BCLAF1-L and upregulates tumor-suppressive BCLAF1-S, regulates alternative splicing of genes such as MDM2 and MDM4, stabilizes p53 protein and induces DNA damage, ultimately triggering tumor cell apoptosis. GPS167 can block the epithelial-mesenchymal transition process of tumors, activate intracellular double-stranded RNA-mediated antiviral immune responses, and produce synergistic cytotoxicity when combined with microtubule-targeting drugs. GPS167 can be used in research related to various cancers including colorectal cancer .
loading...
    loading...
  • 1